{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-000893","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.453022+00:00","generated_at":"2026-05-31T22:31:32.089248+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunic appoints Jason Tardio as COO/President and promotes Werner Gladdines to CDO","bullets":["Jason Tardio, former Novartis MS franchise head and Biogen exec, appointed COO and President effective July 12, 2024.","Tardio will lead launch preparedness for vidofludimus calcium (IMU-838) and partnership efforts.","Compensation: $500,000 base salary, up to 40% bonus, $120,000 signing bonus, and 500,000 stock options with 4-year vest.","Werner Gladdines promoted from VP to Chief Development Officer, overseeing clinical operations.","Phase 2 CALLIPER trial in progressive MS readout expected April 2025; phase 3 ENSURE trials in relapsing MS due 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-000893","json":"https://secwatch.observer/filing/0001193805-24-000893.json","markdown":"https://secwatch.observer/filing/0001193805-24-000893.md","text":"https://secwatch.observer/filing/0001193805-24-000893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000893/0001193805-24-000893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000893/e663765_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:31:32.089248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65dd3b39e8","claim":"Jason Tardio was appointed as Chief Operating Officer and President at IMMUNIC, INC..","evidence_excerpt":"appointment of Jason Tardio as Chief Operating Officer and President, effective July 12, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000893/0001193805-24-000893-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer and President"}],"fact_type":"executive_change"},{"claim_id":"f547c3cc58","claim":"Werner Gladdines changed role as Chief Development Officer at IMMUNIC, INC..","evidence_excerpt":"promotion of Werner Gladdines from Vice President, Program Management & Clinical Development Operations to Chief Development Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000893/0001193805-24-000893-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}